Atlas Trials

AIO-Studien-gGmbH

60 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch AIO-Studien-gGmbH

RecordFirmDate
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden (NCT07715396)AIO-Studien-gGmbH2026-10-30
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome (NCT06380686)AIO-Studien-gGmbH2024-11-07
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NCT05510895)AIO-Studien-gGmbH2022-09-01
Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) (NCT05383001)AIO-Studien-gGmbH2022-05-20
D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (NCT05212012)AIO-Studien-gGmbH2022-02-17
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (NCT05089916)AIO-Studien-gGmbH2022-01-20
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin (NCT05118724)AIO-Studien-gGmbH2021-12-10
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma (NCT05190263)AIO-Studien-gGmbH2021-10-25
Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NCT04727541)AIO-Studien-gGmbH2021-07-08
Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients (NCT04172467)AIO-Studien-gGmbH2020-01-28
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide (NCT04221529)AIO-Studien-gGmbH2020-01-06
A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck (NCT03620123)AIO-Studien-gGmbH2018-07-16
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma (NCT03572582)AIO-Studien-gGmbH2018-06-14
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology (NCT04046614)AIO-Studien-gGmbH2018-05-25
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients (NCT03473574)AIO-Studien-gGmbH2018-05-02
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (NCT03468335)AIO-Studien-gGmbH2018-03-31
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (NCT03409848)AIO-Studien-gGmbH2018-03-01
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (NCT03416244)AIO-Studien-gGmbH2018-02-21
Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers (NCT03193931)AIO-Studien-gGmbH2018-02-02
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (NCT03044587)AIO-Studien-gGmbH2018-01-24
Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma (NCT03317457)AIO-Studien-gGmbH2017-12-15
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (NCT03345810)AIO-Studien-gGmbH2017-12-14
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NCT03043547)AIO-Studien-gGmbH2017-10-24

Track AIO-Studien-gGmbH automatically

Every clearance here is in the API, with alerts when new ones post.